

Session 5:

Saudi FDA Unique Device Identification (UDI)










AGENDA

- ☐ Introduction.
- ☐ SFDA -UDI Requirements & Submission steps.
- ☐ Summary of the experience and the most important considerations for the future



SFDA MD Regulation Framework





Compliance Dates and The current progress

Compliance Timeframe	
Launching the UDI database and starting optional registration for all type of devices	1 st October 2020
Risk Class	Compliance date
Class B & C (Medium risk) Class D (High risk)	1st September 2023
Class A (Low risk)	1st September 2024

Submitted UDI Records (Aug. 2025)

#of Devices 446703

#of Manufacturers 1797



Scope

- ✓ All medical devices & accessories,
- ✓ The manufacturer, or its authorized representative, shall submit and maintain the appropriate data in UDI database


General UDI Requirements include:

- ✓ Recognized issuing Agencies: GS1, HIBCC and ICCBBA
- ✓ The UDI label shall contain two parts: the UDI-DI and the UDI-PI(s).
- ✓ UDI-PI shall include: lot number, serial number, software identification, or expiration (use by) date
- ✓ The UDI shall be readable during normal use and throughout the intended life of the device



UDI in Label

- ✓ The UDI <u>must be presented in two forms</u> on the device label and higher levels of packaging:
- 1. Human Readable Interpretation (HRI): Easily readable plain-text format.
- 2. Automatic Identification and Data Capture (AIDC) Technology: Such as barcodes (linear or 2D) or RFID, enabling automated scanning and data capture.








SAUDI-DI Database

- ➤ The data shall be available in SAUDI-DI database at the time the device is placed on the market.
- Device Records need to be checked and maintained periodically (at least annually) by the manufacturer or its authorized representative
 - ✓ Revisions shall be made within 10 days when the data changes
 - ✓ ensure the data is accurate and consistent with data submitted to GHAD system modules






SFDA Systems









By interring a valid listing number, all relevant information will be retrieved from Marketing Authorization database.

Listing Number

ME0000000091SFDAA00008

Brand Name

test Product by Belal

Manufacturer Name

Test Manufacturer by Belal

Manufacturer Number

ME0000000091

Product Name

test Product by Belal

Authorization Number

MDMA-1-2021-0053

Device Type

Medical Device

Device Classification

Class III

Device Description

12345678900

sterile Device

-

Home Use

No







Primary UDI-DI on the device's primary label, which consider a primary key in

the database and to which other DIs are linked to it

UDI-DI issuing agency is selected from drop-down.

Quantity is number of units in this device or package








Package UDI-DI


- Package Information
- Add levels of the package hierarchy starting from the bigger level.






Summary View of Submission

Upon submission, the summary of the record is displayed.










Bulk upload

- Bulk upload for submitting many records in a single Excel sheet
- All data will be automatically saved and displayed within the Devices records list.
- Any wrong data should be corrected individually through the update action.






Device List page

Icon Actions

- Add Device –to start a new record
- Column Visibility to select the columns displayed
- Excel to export a spreadsheet of records

Search Field







Summary of the experience and the most important considerations for the future

- The implementation of UDI is a crucial initiative that highlights the **commitment to a safe, transparent, and efficient** medical device ecosystem.
- > By establishing clear regulatory requirements ,providing a central database, and implementing a phased compliance approach, the SFDA is actively **enhancing patient safety, improving product traceability**, and bolstering the integrity of the medical device supply chain.
- > The Saudi UDI framework is **aligned** with global guidelines and initiatives.
- The **continued collaboration** among manufacturers, healthcare providers, and the SFDA will be crucial in realizing the full potential of UDI, ultimately contributing to a healthier future for the people of Saudi Arabia.





Summary of the experience and future considerations

- Ongoing efforts are crucial to address potential challenges:
 - Awareness and Education
 - Systems Integration
 - Data Quality and Accuracy
 - Technological Adoption
 - Global Harmonization and Continued collaboration.





Thank You

Contact us at:

md.rs@sfda.gov.sa





